Towards a personalized benefit-risk balance for immunosuppressive therapy in inflammatory bowel disease

Infections, cancers and cardiovascular events are the main events that may be attributable to inflammatory bowel disease (IBD) and/or IBD treatment. Immunosuppressive drugs have been shown to promote immunosuppression-related infections and cancers. Via mucosal healing, immunosuppressive drugs should be able to reduce the incidence of infections related to intestinal lesions, malnutrition, intravenous devices and IBD surgery, and to reduce the incidence of cancers attributable to chronic mucosal inflammation.

https://ift.tt/2zSRSwu